{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2&page=28", "query": { "intervention": "Dose 2", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 31368, "total_pages": 3137, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2&page=29&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2&page=27&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T00:40:06.430Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06356571", "title": "A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma Refractory" ], "interventions": [ { "name": "Isatuximab SC-OBDS", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2025-03-17", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06356571" }, { "nct_id": "NCT01971164", "title": "Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anemia of Chronic Kidney Disease" ], "interventions": [ { "name": "JTZ-951", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akros Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2013-05", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2014-07-14", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 5, "location_summary": "Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Lakewood", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01971164" }, { "nct_id": "NCT01437709", "title": "Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Ofatumumab (This arm is closed)", "type": "BIOLOGICAL" }, { "name": "Ofatumumab + Bendamustine", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2011-09", "completion_date": "2023-09-12", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01437709" }, { "nct_id": "NCT05596409", "title": "ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Elacestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemline Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2023-05-19", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 4, "location_summary": "Springdale, Arkansas • Chicago, Illinois • Las Vegas, Nevada + 1 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05596409" }, { "nct_id": "NCT02500199", "title": "Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Gastric Cancer", "Solid Tumors", "NSCLC" ], "interventions": [ { "name": "Pyrotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hengrui Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-06", "completion_date": "2021-06", "has_results": false, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 10, "location_summary": "Orange, California • Sacramento, California • Sarasota, Florida + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500199" }, { "nct_id": "NCT06405087", "title": "A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab SC", "type": "DRUG" }, { "name": "No Intervention", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 70, "start_date": "2025-10-27", "completion_date": "2030-08-12", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Loma Linda, California • Orange, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06405087" }, { "nct_id": "NCT03802916", "title": "Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iron Overload Due to Repeated Red Blood Cell Transfusions" ], "interventions": [ { "name": "Deferiprone DR tablets 1000 mg (Low dosage)", "type": "DRUG" }, { "name": "Deferiprone DR tablets 1000 mg (High dosage)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ApoPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-03-06", "completion_date": "2019-12-19", "has_results": true, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03802916" }, { "nct_id": "NCT06916806", "title": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Idiopathic Inflammatory Myopathies", "Rheumatoid Arthritis" ], "interventions": [ { "name": "AZD5492", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2025-05-01", "completion_date": "2027-09-15", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 7, "location_summary": "Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 4 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06916806" }, { "nct_id": "NCT03672604", "title": "A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety and Tolerability in Healthy Volunteers" ], "interventions": [ { "name": "NLY01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neuraly, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 96, "start_date": "2018-09-19", "completion_date": "2019-07-30", "has_results": false, "last_update_posted_date": "2019-09-30", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03672604" }, { "nct_id": "NCT04182633", "title": "MTT for Children With ASD Who Have Gastrointestinal Disorders", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism Spectrum Disorder", "Gastro-Intestinal Disorder", "Constipation", "Diarrhea" ], "interventions": [ { "name": "vancomycin, Miralax, intestinal microbiota", "type": "COMBINATION_PRODUCT" }, { "name": "placebo vancomycin, Miralax, placebo intestinal microbiota", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Arizona State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 50, "start_date": "2019-11-15", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-10-25T00:40:06.430Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04182633" } ] }